Dedifferentiated Carcinoma of the Endometrium Associated With Low-grade Müllerian Adenosarcoma: A Clinicopathologic Case Report Including the Immunohistochemical and Molecular Profile.
Journal
International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
ISSN: 1538-7151
Titre abrégé: Int J Gynecol Pathol
Pays: United States
ID NLM: 8214845
Informations de publication
Date de publication:
Mar 2020
Mar 2020
Historique:
pubmed:
26
3
2019
medline:
3
11
2020
entrez:
26
3
2019
Statut:
ppublish
Résumé
Dedifferentiated carcinoma is defined as undifferentiated carcinoma coexisting with a second component of FIGO grade 1 or 2 endometrioid carcinoma. It is a rare entity with highly aggressive behavior. Dedifferentiated carcinoma combined with another primary uterine tumor is even rarer. We describe a case containing 3 different morphologies comprised of a dedifferentiated carcinoma associated with a low-grade endometrioid carcinoma coexisting with a low-grade Müllerian adenosarcoma. We also used targeted genomic analysis to show all 3 components arise from the same founding clone and identify novel mutations that drive tumor progression.
Identifiants
pubmed: 30908285
doi: 10.1097/PGP.0000000000000584
pii: 00004347-202003000-00007
doi:
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
141-145Références
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin 2018;68:7–30.
Lu Z, Chen J. Introduction of WHO classification of tumours of female reproductive organs, fourth edition. Zhonghua Bing Li Xue Za Zhi 2014;43:649–50.
Silva EG, Deavers MT, Bodurka DC, et al. Association of low-grade endometrioid carcinoma of the uterus and ovary with undifferentiated carcinoma: a new type of dedifferentiated carcinoma? Int J Gynecol Pathol 2006;25:52–8.
Lee SE, Park HY, Shim SH, et al. Dedifferentiated carcinoma with clear cell carcinoma of the endometrium: a case report. Pathol Int 2017;67:472–6.
Liu Q, Cornejo KM, Cheng L, et al. Next-generation sequencing to detect deletion of RB1 and ERBB4 genes in chromophobe renal cell carcinoma: a potential role in distinguishing chromophobe renal cell carcinoma from renal oncocytoma. Am J Pathol 2018;188:846–52.
Broaddus RR, Lynch HT, Chen LM, et al. Pathologic features of endometrial carcinoma associated with HNPCC: a comparison with sporadic endometrial carcinoma. Cancer 2006;106:87–94.
Tafe LJ, Garg K, Chew I, et al. Endometrial and ovarian carcinomas with undifferentiated components: clinically aggressive and frequently underrecognized neoplasms. Mod Pathol 2010;23:781–9.
Giordano G, Tiziana D, Lorena B, et al. Two cases of low-grade endometriod carcinoma associated with undifferentiated carcinoma of the uterus (dedifferentiated carcinoma): a molecular study. Pathol Oncol Res 2012;18:523–8.
Forbes SA, Bindal N, Bamford S, et al. COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res 2011;39:D945–50.
Oda K, Stokoe D, Taketani Y, et al. High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma. Cancer Res 2005;65:10669–73.
Hodgson A, Amemiya Y, Seth A, et al. High-grade Mullerian adenosarcoma: genomic and clinicopathologic characterization of a distinct neoplasm with prevalent TP53 pathway alterations and aggressive behavior. Am J Surg Pathol 2017;41:1513–22.
Howitt BE, Sholl LM, Dal CP, et al. Targeted genomic analysis of Mullerian adenosarcoma. J Pathol 2015;235:37–49.
Huang Z, Wu T, Liu AY, et al. Differentiation and transdifferentiation potentials of cancer stem cells. Oncotarget 2015;6:39550–63.
Kuhn E, Ayhan A, Bahadirli-Talbott A, et al. Molecular characterization of undifferentiated carcinoma associated with endometrioid carcinoma. Am J Surg Pathol 2014;38:660–5.
Martin Martorell P, Huerta M, Compan Quilis A, et al. Coexistence of EGFR, KRAS, BRAF, and PIK3CA mutations and ALK rearrangement in a comprehensive cohort of 326 consecutive spanish nonsquamous NSCLC patients. Clin Lung Cancer 2017;18:e395–402.
Shtivelman E, Davies MQ, Hwu P, et al. Pathways and therapeutic targets in melanoma. Oncotarget 2014;5:1701–52.